A new study reports that people with type 2 diabetes who begin treatment with GLP-1 receptor agonists (such as Ozempic) and later stop may face worse cardiovascular outcomes than those who remain on therapy. The research, published in The Lancet Regional Health—Europe, finds higher combined risk of heart attack, stroke, or death among patients who stop after starting, compared with patients who continue treatment.

Both outlets describe the same overall finding: stopping after initiation is associated with poorer health outcomes for a subgroup of people with type 2 diabetes who do not have established cardiovascular disease. Medical Xpress focuses on the specific cardiovascular endpoints highlighted by the study, while ABC Australia frames the results more generally as a “starting and stopping” pattern that warrants further research. Neither source suggests that patients should stop medication; instead, they emphasize that the association needs additional study and context.

Overall, the differing angles come down to how closely each outlet spotlights the cardiovascular outcome details versus the broader “start-stop” implication and the need for more evidence.